Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis
Ram P. Naikawadi, Supparerk Disayabutr, Benat Mallavia, Matthew L. Donne, Gary Green, Janet L. La, Jason R. Rock, Mark R. Looney, Paul J. Wolters
Ram P. Naikawadi, Supparerk Disayabutr, Benat Mallavia, Matthew L. Donne, Gary Green, Janet L. La, Jason R. Rock, Mark R. Looney, Paul J. Wolters
View: Text | PDF
Resource and Technical Advance Pulmonology

Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis

  • Text
  • PDF
Abstract

Telomeres are short in type II alveolar epithelial cells (AECs) of patients with idiopathic pulmonary fibrosis (IPF). Whether dysfunctional telomeres contribute directly to development of lung fibrosis remains unknown. The objective of this study was to investigate whether telomere dysfunction in type II AECs, mediated by deletion of the telomere shelterin protein TRF1, leads to pulmonary fibrosis in mice (SPC-Cre TRF1fl/fl mice). Deletion of TRF1 in type II AECs for 2 weeks increased γH2AX DNA damage foci, but not histopathologic changes in the lung. Deletion of TRF1 in type II AECs for up to 9 months resulted in short telomeres and lung remodeling characterized by increased numbers of type II AECs, α-smooth muscle actin+ mesenchymal cells, collagen deposition, and accumulation of senescence-associated β-galactosidase+ lung epithelial cells. Deletion of TRF1 in collagen-expressing cells caused pulmonary edema, but not fibrosis. These results demonstrate that prolonged telomere dysfunction in type II AECs, but not collagen-expressing cells, leads to age-dependent lung remodeling and fibrosis. We conclude that telomere dysfunction in type II AECs is sufficient to cause lung fibrosis, and may be a dominant molecular defect causing IPF. SPC-Cre TRF1fl/fl mice will be useful for assessing cellular and molecular mechanisms of lung fibrosis mediated by telomere dysfunction.

Authors

Ram P. Naikawadi, Supparerk Disayabutr, Benat Mallavia, Matthew L. Donne, Gary Green, Janet L. La, Jason R. Rock, Mark R. Looney, Paul J. Wolters

×

Figure 5

Telomere dysfunction in type II AECs causes cellular senescence and hyperplasia.

Options: View larger image (or click on image) Download as PowerPoint
Telomere dysfunction in type II AECs causes cellular senescence and hype...
(A) Senescence-associated β-galactosidase (SA-β-gal) staining of sections of lung harvested from TRF1fl/fl and SPC-Cre TRF1fl/fl mice following 8 months of weekly injections of tamoxifen (250 mg/kg body weight). Note the blue SA-β-gal+ cells (arrows) in lungs of SPC-Cre TRF1fl/fl mice but not in TRF1fl/fl mice. (B) SA-β-gal activity was detected in 43.4% of type II AECs isolated from SPC-Cre TRF1fl/fl lungs compared with 9.5 % of type II AECs isolated from TRF1fl/fl mice when analyzed by flow cytometry. (C–F) Immunostaining of SPC (red) in sections of lung harvested from TRF1fl/fl and SPC-Cre TRF1fl/fl mice treated with weekly tamoxifen injections for 2 weeks (D), 3 months (E) or 8 months (C and F). Note the increased density of type II AECs in SPC-Cre TRF1fl/fl lung sections at the 8-month time point. Nuclei were stained with DAPI (blue). Scale bars: 50 μm. (G) Quantification of type II AECs. n = 6 mice/group, ***P < 0.0001, 1-way ANOVA. (H) Immunostaining of α-smooth muscle actin (α-SMA, green) in sections of lung harvested from TRF1fl/fl and SPC-Cre TRF1fl/fl mice treated with weekly tamoxifen injections for 8 months. α-SMA+ cells (green) indicated by white arrows. DAPI (blue). Scale bar: 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts